TABLE 2.
Antimicrobial susceptibility patternsa
| Strain | Susceptibility by Etest (MIC [mg/liter]) |
Susceptibility by agar disc diffusion (zone diam [mm]) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| MEM | IPM | CIP | CTX | CAZ | CST | TOB10 | GEN10 | AMK30 | |
| A068 | R (16) | R (32) | R (>32) | R (>256) | R (>256) | S (0,25) | R (6) | R (6) | R (6) |
| A069 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.125) | R (6) | R (6) | R (6) |
| A070 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.25) | R (6) | R (6) | R (6) |
| A071 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.5) | R (6) | R (6) | R (6) |
| A072 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.25) | R (6) | R (6) | R (6) |
| A074 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.25) | S (17) | R (6) | R (6) |
| A076 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.25) | R (11) | R (6) | S (21) |
| A077 | R (>32) | R (>32) | R (>32) | R (>256) | R (>256) | S (0.25) | S (18) | R (6) | S (20) |
| A078 | R (>32) | R (>32) | R (>32) | R (>256) | R (>256) | S (0.25) | R (6) | R (6) | R (9) |
| A079 | R (>32) | R (>32) | R (>32) | R (>256) | R (>256) | S (0.125) | R (6) | R (6) | R (6) |
| A080 | R (>32) | R (>32) | R (>32) | R (>256) | R (>256) | S (0.25) | R (6) | R (6) | R (6) |
| A082 | R (16) | I (8) | R (>32) | R (>256) | R (>256) | S (0.25) | R (12) | R (6) | R (9) |
| A084 | R (>32) | R (>32) | R (>32) | R (>256) | R (>256) | S (0.5) | S (19) | R (8) | R (8) |
| A085 | R (>32) | R (>32) | R (>32) | R (>256) | R (256) | S (0.5) | R (14) | R (10) | I (15) |
| A086 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.125) | R (6) | R (6) | R (6) |
| A087 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.125) | S (18) | R (6) | R (6) |
| A089 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.125) | R (6) | R (6) | R (6) |
| A091 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.25) | R (6) | R (6) | R (6) |
| A092 | R (32) | R (32) | R (32) | R (256) | R (256) | S (1) | R (6) | R (6) | R (6) |
| A093 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.25) | R (6) | R (6) | R (6) |
| A094 | R (32) | R (32) | R (32) | I (32) | S (8) | S (0.25) | R (6) | R (6) | R (6) |
| A095 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.5) | R (6) | R (6) | R (6) |
| A096 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.25) | R (6) | R (6) | R (6) |
| A097 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.25) | R (6) | R (6) | R (6) |
| A099 | I (8) | R (16) | R (32) | R (256) | R (32) | S (0.125) | S (18) | R (8) | R (10) |
| A100 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.125) | R (7) | R (6) | R (8) |
| A101 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.125) | S (19) | S (19) | R (10) |
| A105 | R (32) | R (32) | R (32) | R (256) | R (256) | S (0.125) | S (19) | R (6) | R (8) |
MEM, meropenem; IPM, imipenem; CIP, ciprofloxacin; CTX, cefotaxime; CAZ, ceftazidime; CST, colistin; TOB10, tobramycin at 10 mg/liter; GEN10, gentamicin at 10 mg/liter; AMK30, amikacin at 30 mg/liter; R, resistant; I, intermediate; S, susceptible. The results were interpreted according to the following clinical breakpoints, as defined by EUCAST (http://www.eucast.org/clinical_breakpoints/) and/or according to the Clinical and Laboratory Standards Institute breakpoints (CLSI document M100-S24, 2014 [17]): for meropenem and imipenem, susceptible was an MIC of ≤2 mg/liter and resistant was an MIC of >8 mg/liter; for ciprofloxacin, susceptible was an MIC of ≤1 mg/liter and resistant was an MIC of >1 mg/liter; for cefotaxime, susceptible was an MIC of ≤8 mg/liter, intermediate was an MIC of 16 to 32 mg/liter, and resistant was an MIC of ≥64 mg/liter; for ceftazidime, susceptible was an MIC of ≤8 mg/liter, intermediate was an MIC of 16 mg/liter, and resistant was an MIC of ≥32 mg/liter; for colistin, susceptible was an MIC of ≤2 mg/liter and resistant was an MIC of >2 mg/liter; for tobramycin at 10 mg/liter, susceptible was an MIC of ≥17 mg/liter and resistant was an MIC of <17 mg/liter; for gentamicin at 10 mg/liter, susceptible was an MIC of ≥17 mg/liter and resistant was an MIC of <17 mg/liter; and for amikacin at 30 mg/liter, susceptible was an MIC of ≥18 mg/liter and resistant was an MIC of <15 mg/liter).